Funded by the Helmsley Charitable Trust, CD-metaRESPONSE will recruit 300 patients with Crohn's disease to investigate the metabolites produced by the gut microbiome (known as metabolomics), and how they change in response to initiation of biologic or JAK inhibitor treatment.
Metabolomic data will provide an understanding of the functional capacity of the gut microbiome, and will be investigated from patients' stool and blood samples.
This data will accompany information about the gut microbiome from IBD-RESPONSE, and will allow predictive modelling of treatment response outcomes.
